BioAtla, Inc.
About BioAtla, Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2021
- $300.0K
- Net income
- -$59.6M
- Total assets
- $13.8M
- Market cap
- $5.5M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $5.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 16, 2020
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review BioAtla, Inc..
